PL1626736T3 - Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego - Google Patents

Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego

Info

Publication number
PL1626736T3
PL1626736T3 PL04748575T PL04748575T PL1626736T3 PL 1626736 T3 PL1626736 T3 PL 1626736T3 PL 04748575 T PL04748575 T PL 04748575T PL 04748575 T PL04748575 T PL 04748575T PL 1626736 T3 PL1626736 T3 PL 1626736T3
Authority
PL
Poland
Prior art keywords
inhibitor
life
short half
transient treatment
transient
Prior art date
Application number
PL04748575T
Other languages
English (en)
Inventor
Johannes Henricus Nuijens
Original Assignee
Pharming Intellectual Property B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B.V. filed Critical Pharming Intellectual Property B.V.
Publication of PL1626736T3 publication Critical patent/PL1626736T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04748575T 2003-05-16 2004-05-14 Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego PL1626736T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03076466 2003-05-16
EP04748575.0A EP1626736B1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life for transient treatment
PCT/NL2004/000330 WO2004100982A1 (en) 2003-05-16 2004-05-14 C1 inhibitor with short half-life for transient treatment

Publications (1)

Publication Number Publication Date
PL1626736T3 true PL1626736T3 (pl) 2021-05-04

Family

ID=33442800

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04748575T PL1626736T3 (pl) 2003-05-16 2004-05-14 Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego

Country Status (15)

Country Link
US (2) USRE43691E1 (pl)
EP (1) EP1626736B1 (pl)
JP (1) JP2007500741A (pl)
CN (1) CN100431604C (pl)
AU (1) AU2004238170B2 (pl)
CA (1) CA2525522A1 (pl)
CY (1) CY1123601T1 (pl)
DK (1) DK1626736T3 (pl)
ES (1) ES2830499T3 (pl)
HU (1) HUE052154T2 (pl)
NZ (1) NZ543646A (pl)
PL (1) PL1626736T3 (pl)
PT (1) PT1626736T (pl)
SI (1) SI1626736T1 (pl)
WO (1) WO2004100982A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502539A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
DK1626736T3 (da) * 2003-05-16 2020-09-28 Pharming Intellectual Property B V C1-inhibitor med kort halveringstid til midlertidig behandling
JP5118492B2 (ja) 2004-12-23 2013-01-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血栓の形成の防止および／または安定化の防止
CN101365478B (zh) * 2005-12-21 2016-06-22 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
SI2380587T1 (en) * 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
NZ576195A (en) * 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
ES2646191T3 (es) * 2011-03-09 2017-12-12 Csl Behring Gmbh Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US20160058850A1 (en) * 2012-11-13 2016-03-03 Biogenius Llc Compositions and methods for treating inflammatory diseases of infectious and non-infectious origin
US10441631B2 (en) * 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
SMT201700415T1 (it) 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US20150104445A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
CA2940670A1 (en) * 2014-02-28 2015-09-03 Santarus, Inc. Treatment of hereditary angioedema with c1 inhibitor
KR20210005549A (ko) 2018-02-28 2021-01-14 파밍 인텔렉츄얼 프라퍼티 비.브이. 전자간증의 치료 및 예방
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP3895726A1 (en) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
AU658560B2 (en) 1989-10-27 1995-04-27 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US6713662B1 (en) 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
DE122011000002I1 (de) * 2000-01-31 2011-05-05 Pharming Intellectual Pty Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7229665B2 (en) * 2001-05-22 2007-06-12 Millipore Corporation Process of forming multilayered structures
DK1626736T3 (da) * 2003-05-16 2020-09-28 Pharming Intellectual Property B V C1-inhibitor med kort halveringstid til midlertidig behandling

Also Published As

Publication number Publication date
PT1626736T (pt) 2020-10-13
ES2830499T3 (es) 2021-06-03
US7544853B2 (en) 2009-06-09
SI1626736T1 (sl) 2021-04-30
EP1626736A1 (en) 2006-02-22
AU2004238170A1 (en) 2004-11-25
CN1791425A (zh) 2006-06-21
US20070185011A1 (en) 2007-08-09
CN100431604C (zh) 2008-11-12
CY1123601T1 (el) 2022-03-24
NZ543646A (en) 2009-09-25
CA2525522A1 (en) 2004-11-25
JP2007500741A (ja) 2007-01-18
HUE052154T2 (hu) 2021-04-28
EP1626736B1 (en) 2020-09-16
DK1626736T3 (da) 2020-09-28
AU2004238170B2 (en) 2009-11-05
USRE43691E1 (en) 2012-09-25
WO2004100982A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
EG25482A (en) Inhibitors
HUE052154T2 (hu) Rövid felezési idejû C1 inhibitor tranziens kezeléshez
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
EP1676582A4 (en) AGENT CONTROLLING CORONAVIRUS
GB0306179D0 (en) Piping
AU150842S (en) Back wrap
AU2003230392A8 (en) Beta-secretase inhibitors
GB0305989D0 (en) Agent
GB0507625D0 (en) Bookmark
ZA200409691B (en) Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors
TW529456U (en) Pipeline for mixing
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0306166D0 (en) Pipeline protection
GB0312619D0 (en) Complement inhibitors
TW566734U (en) Power extension line for computer
GB0324783D0 (en) Bookmark
IL165935A (en) Vasopeptidase inhibitors
IL173608A0 (en) 15-d-homosteroids having an androgenic effect
GB0329869D0 (en) Inhibitors
GB0300607D0 (en) Inhibitors
PL351729A1 (en) Bench
GB0327386D0 (en) Complement inhibitors
HU0301894D0 (en) Wood-protecting composition for general purpose
GB0326295D0 (en) Bookmark
AU153640S (en) Bookmark